Q-omics provides the consensus-scored TMPRSS11F profile across patient tissues and cancer cell-line models. TMPRSS11F expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMPRSS11F is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, TMPRSS11F RNA expression shows 12,004 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUSC, and UVM as cancer lineages where TMPRSS11F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMPRSS11F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMPRSS11F survival associations across molecular data types. TMPRSS11F RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMPRSS11F RNA expression–survival associations across cancer types. High TMPRSS11F expression shows unfavorable associations in KIRC, LUAD, KICH and BLCA, but favorable associations in LUSC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMPRSS11F RNA expression.
This table summarizes TMPRSS11F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMPRSS11F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMPRSS11F shows higher tumor expression in LUSC, KIRC, THCA, PRAD, CHOL and LUAD. The LUSC box plot shows higher TMPRSS11F RNA expression in tumor versus normal tissue (log2 FC = +1.863, t-test p < 0.001).
This table shows molecular features associated with TMPRSS11F in patient tissues and cancer cell lines. In patient samples, TMPRSS11F shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMPRSS11F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
